Inhibrx Current Deferred Revenue from 2010 to 2025
| INBX Stock | USD 14.43 0.36 2.43% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 149.4 K | Current Value 141.9 K | Quarterly Volatility 1.9 M |
Check Inhibrx Biosciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx Biosciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Selling General Administrative of 134.3 M or Selling And Marketing Expenses of 202.4 K, as well as many indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0522 or PTB Ratio of 1.75. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Biosciences, Valuation or Volatility modules.
Inhibrx | Current Deferred Revenue | Build AI portfolio with Inhibrx Stock |
Latest Inhibrx Biosciences,'s Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Inhibrx Biosciences, over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Inhibrx Biosciences,'s Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx Biosciences,'s overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Inhibrx Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,260,271 | |
| Geometric Mean | 1,334,487 | |
| Coefficient Of Variation | 82.41 | |
| Mean Deviation | 1,159,162 | |
| Median | 2,607,000 | |
| Standard Deviation | 1,862,715 | |
| Sample Variance | 3.5T | |
| Range | 7.8M | |
| R-Value | (0.39) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | (153,479) | |
| Total Sum of Squares | 52T |
Inhibrx Current Deferred Revenue History
About Inhibrx Biosciences, Financial Statements
Inhibrx Biosciences, investors use historical fundamental indicators, such as Inhibrx Biosciences,'s Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx Biosciences,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 149.4 K | 141.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx Biosciences,'s price analysis, check to measure Inhibrx Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences, is operating at the current time. Most of Inhibrx Biosciences,'s value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences,'s price. Additionally, you may evaluate how the addition of Inhibrx Biosciences, to your portfolios can decrease your overall portfolio volatility.